Researchers sought to explore biomarkers in pre- and on- treatment mCRC patients receiving chemotherapy with and without cediranib, in order to identify patient subgroups who may benefit from the combination cediranib therapy.
https://www.nature.com/bjc/journal/vaop/ncurrent/full/bjc2014436a.html
